MedTrace Logo

The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.

NCT04691063 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 486

Last updated 2021-02-26

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.

Conditions

  • Small-cell Lung Cancer

Interventions

DRUG

SHR-1316; Carboplatin; Etoposide；Radiotherapy

SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）

DRUG

Palcebo; Carboplatin; Etoposide；Radiotherapy

Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-22
Primary Completion
2025-05-15
Completion
2025-05-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04691063 on ClinicalTrials.gov